HV-107 / University of Puerto Rico - LARVOL DELTA

The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer. (PubMed, Mol Med) - "The findings indicate that HV-107 exhibits promising potential as a therapeutic medication utilizing Rac inhibition mechanisms to address metastasis formation in TNBC."

Journal • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CDC42 • PAK2

Rac inhibitors for cancer therapy (AACR 2022) - "A decrease of ~ 40% in liver metastasis was shown for mice treated with 5 mg/kg BW HV-107. Taken together, our results indicate HV-107 and HV-118 are approximately 4-100 times more efficient than the parent compound Ehop-016 and have potential as anti-breast cancer metastasis therapeutics.This study is supported by NIH Grant 1SC1GM122691, and PRINBRE P20GM103475 from NIGMS of the NIH to GVC"

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

The Rac inhibitors HV-107 and HV-118 as potential therapeutics for metastatic breast cancer (AACR 2019) - "Taken together, our results indicate HV-107 and HV-118 have potential as anti-breast cancer metastasis therapeutics. This study was supported by awards from the Susan Komen for the Cure, NIH/NIMHHD U54MD008149, and the Puerto Rico Science and Technology Trust to SD; NIH/NCRR R25GM061838 to UPR MSC; NIH/NIMHHD RCMI 8G12MD007583RCMI, Title V PPOHA 031M10505 and Title V Cooperative P031S130068 from U.S. Department of Education to UCC; and and PRINBRE (NIH/NIGMS P20GM103475-13) Sub-Award to LCP."